Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Published on 20/02/202521/02/2025 by Top Pharmaceutical

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Dr Kanwaljit Rana,Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India, India

Dr. Kanwaljit Rana 🧬📊 is a health researcher specializing in computational biology and big data analytics for disease diagnosis and health outcome prediction. Holding a Ph.D. in Biotechnology from GADVASU, India (2022), Dr. Rana integrates large-scale clinical, biological, and omics data using machine learning for precision medicine. With research experience at ICGEB and PGIMER, he has developed bioinformatics pipelines for genomics and predictive health analytics. His expertise spans AI-driven diagnostics, wearable health tech, and big data automation. A published scientist and GATE-qualified scholar, Dr. Rana continues to innovate in health data science and computational medicine. 🚀

Publication Profile

Google scholar

Education

Dr. Kanwaljit Rana 🎓 holds a Ph.D. in Biotechnology from Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), India (2022). With a strong academic foundation, he previously earned a Master’s degree in Biotechnology from HNB Garhwal University, Srinagar. His expertise lies in cutting-edge biotechnological research, contributing to advancements in veterinary and animal sciences 🧬🔬. Passionate about innovation and scientific discovery, Dr. Rana continues to explore new frontiers in biotechnology, striving to make a meaningful impact in the field. His dedication to research and development reflects his commitment to scientific excellence and progressive learning

Professional Experience

Dr. Kanwaljit Rana 🎓 is a dedicated Research Associate at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (Feb 2024 – Aug 2024), where he conducts advanced bioinformatics analysis 🧬, integrating genomics and metagenomics data for disease characterization. Previously, at PGIMER, Chandigarh (Sep 2022 – Jan 2023), he developed automated workflows for tuberculosis meningitis diagnosis 🏥. His research journey includes roles at Punjab Agricultural University (PAU), Ludhiana, and Swami Vivekanand Faculty of Technology & Management, specializing in molecular breeding 🌱 and agricultural biotechnology. He is also a QC Freelancer at Cactus Communications since October 2024 ✍️.

Awards

Dr. Kanwaljit Rana 🎓 is a highly accomplished researcher, having qualified GATE Biotechnology in both 2020 and 2022 🏆, showcasing his expertise in the field. His dedication to innovative research earned him the Best Poster Award 🥇 for his work on “Boon of Cow Curd Consumption” at the National Webinar on Cowpathy and Animal Health (2021) 🐄🧪. His contributions to biotechnology and health sciences continue to make a significant impact, blending traditional knowledge with modern scientific advancements. Dr. Rana remains committed to groundbreaking research and advancements in biotechnology and health sciences 🔬📚

Research Focus

Dr. Kanwaljit Rana’s research primarily focuses on computational genomics 🧬, bioinformatics 🖥️, and veterinary genetics 🐶. His work involves biocomputational analysis of microRNAs, genome assembly, and ancestry studies, particularly in indigenous dog breeds like the Gaddi dog. His expertise extends to genome sequencing, phylogenetics, and the application of programming languages like Python, R, and MATLAB for data analysis. His contributions to veterinary science include genetic insights into animal breeding, evolution, and conservation. Through his interdisciplinary approach, Dr. Rana advances animal genomics, computational biology, and veterinary research, impacting both genetic conservation and bioinformatics applications in animal sciences.

Publication Top Notes

Differential Perspectives Between miRNA and lncRNA in Light of Biogenesis and Functions: A Review

Molecular characterization of indigenous dogs through whole genome analysis

Biocomputational identification of microRNAs from indigenous Gaddi dog genome

Introduction to Python, R, and MATLAB

SON DINH PHONG | Gene Therapy | Best Researcher Award

Published on 20/02/202521/02/2025 by Top Pharmaceutical

SON DINH PHONG | Gene Therapy | Best Researcher Award

Dr SON DINH PHONG, DUYTAN UNIVERSITY, Vietnam

Dr. Dinh Phong Son is a dedicated researcher in molecular medicine at Duy Tan University, Vietnam. With a Ph.D. from Guangxi Medical University, China, and a background in laboratory medicine from Hue University of Medicine and Pharmacy, his research focuses on molecular biomarkers for early disease detection 🧪🔬. He explores the LncRNA/CircRNA/miRNA/gene/protein-drug interaction network and gene-editing techniques like CRISPR/Cas9 for targeted therapy. His work on cardiovascular disease and cancer diagnostics has been published in prestigious journals 📚🧑‍🔬. Passionate about advancing molecular biology, he aspires to contribute to innovative breakthroughs in disease research.

Publication Profile

orcid

Education

Dr. Dinh Phong Son 🎓 holds a degree in Laboratory Medicine Technique from Hue University of Medicine and Pharmacy, Vietnam, and a Ph.D. in Molecular Medicine from Guangxi Medical University, China. 🧬 His expertise lies in molecular biology, with a strong focus on disease biomarkers and gene-targeted therapies. 🏥🔬 With a solid academic foundation, he has contributed significantly to scientific advancements, particularly in precision medicine and diagnostics. His research aims to enhance medical treatments by identifying key genetic markers, paving the way for innovative therapeutic approaches. 🌍✨ Dr. Son’s dedication to science continues to drive breakthroughs in healthcare. 💡👨‍⚕️

Research and Innovations

Dr. Son Dinh Phong 🔬 is deeply engaged in advancing molecular biology through next-generation sequencing and online medical databases. His primary focus is identifying potential biomarkers for early disease detection, including diabetes, cardiovascular diseases, stroke, and cancer. 🧬🩺 His research also explores gene-targeted therapies, utilizing CRISPR/Cas9 for gene editing, overexpression, and silencing. 🏥 His studies on LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks provide a foundation for future medical breakthroughs. 📊✨ Committed to innovation, Dr. Son’s ongoing work (2023-2025) aims to drive scientific progress, hoping for greater support to expand molecular biology research worldwide. 🌍💡

Research Contributions

Dr. Son Dinh Phong 🔬 is highly proficient in advanced molecular biology techniques, including PCR, qPCR, and sequencing analysis 🧪🧬. He specializes in CRISPR/Cas9 genome editing, RNA silencing, and overexpression assays, contributing to groundbreaking gene therapy research. 🏥 His expertise also includes cell culture, western blotting, and fluorescence in situ hybridization, essential for studying gene expression and protein interactions. 🔍🧫 Additionally, he excels in bioinformatics and molecular docking simulations, enabling in-depth analysis of gene interactions and drug responses. 💻💊 With a strong foundation in computational biology, Dr. Son continues to drive innovation in precision medicine and molecular diagnostics. 🚀✨

Editorial Appointments

Dr. Son Dinh Phong 🌍🔬 actively contributes to the global scientific community through his extensive research and publications. While specific editorial roles, consultancy projects, or industry collaborations may not be listed, his scholarly work reflects deep engagement in molecular biology and precision medicine. 🧬📖 His ORCID profile further validates his impactful contributions, showcasing his dedication to advancing medical research. 🏥✨ Through collaborations and scientific discourse, Dr. Son continues to push the boundaries of innovation, striving to enhance disease diagnostics and therapeutic strategies. His commitment to research ensures lasting contributions to the ever-evolving field of molecular medicine. 💡🚀

Research Focus

Dr. Son Dinh Phong’s research primarily focuses on cardiovascular diseases 🫀, non-coding RNAs 🧬, and bioinformatics-driven biomarker discovery 🖥️. His work explores circular RNAs (circRNAs) and microRNAs (miRNAs) in coronary heart disease (CHD) 🏥, revealing their role as competing endogenous RNAs (ceRNAs) in gene regulation. Additionally, he investigates serum miRNAs as potential diagnostic biomarkers for various cancers 🎗️ and employs computational approaches 🔬 to identify key regulatory networks in diseases like latent tuberculosis 🦠. His studies integrate molecular biology, genomics, and systems biology to advance precision medicine 🎯 and therapeutic innovations 💊 for complex diseases.

Publication Top Notes

Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation

Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1

Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data

Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease

Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis

Prakriti Sharma | Respiratory Pharmacology | Women Researcher Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Prakriti Sharma | Respiratory Pharmacology | Women Researcher

Award

Dr Prakriti Sharma, GADVASU, Ludhiana,India

Dr. Prakriti Sharma 🎓🔬 is a biotechnology researcher specializing in cancer immunology and NFAT signaling. She earned her Ph.D. from Guru Angad Dev Veterinary and Animal Sciences University (2022) and has worked as a Project Associate at CSIR-IMTECH, Chandigarh. Her research explores lung inflammation, bioactive molecules, and cancer therapy. She has received multiple awards for her publications on pesticide impact and nanocarrier-based drug delivery. Dr. Sharma has teaching experience and has contributed to leading journals like Journal of Toxicology and iScience. Her expertise spans molecular biology, immunology, and therapeutic innovations. 📚🧬

Publication Profile

orcid

Education

Dr. Prakriti Sharma 🎓 holds a Master’s degree in Biotechnology from HNB Garhwal University, Srinagar (2013) and earned her Ph.D. in Biotechnology from Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana (June 2022). Her doctoral research focused on Nuclear Factor of Activated T-Cell Signaling during Deltamethrin-Induced Lung Damage 🧬. She has worked as a Project Associate at CSIR-IMTECH, Chandigarh (2022–2024), specializing in cancer immunology and biology 🏥🔬. With a strong background in biotechnology, Dr. Sharma is dedicated to advancing scientific research in immunology and disease mechanisms, contributing to the field with her expertise and innovative approach.

Awards

Dr. Prakriti Sharma 🎓 has received several prestigious awards and honors in her academic journey. She qualified for the GATE Examination in Biotechnology in 2018 🏆 and was selected for the GEFSES-CREATE training program (2019–2020) 🔬. Her research contributions have been recognized with multiple Best Article awards 📝, including “Pesticide Residues in Food”, “Pesticide Usage and Its Impact on Biodiversity”, and “Common Routes of Pesticide Exposure and Its Protective Measures”, published in Agriculture & Food: e-Newsletter 🌿📖. Her dedication to biotechnology and environmental safety continues to make a significant impact in the field.

Teaching Experience

Dr. Prakriti Sharma 🎓 has gained extensive research and teaching experience in biotechnology and agriculture. She completed a three-month dissertation on Diversity and Characterization of Plant Growth-Promoting Rhizobacteria 🌱 at Dolphin PG Institute, Dehradun. She worked as a Project Fellow in the PlaGen scheme at CSIR-IHBT, Palampur (2015–2016) 🧬. Dr. Sharma also served as an Assistant Professor in Agriculture at Swami Vivekanand Faculty of Technology & Management (2017–2018) 📚. Most recently, she was a Project Associate at CSIR-IMTECH, Chandigarh (2022–2024) 🔬, contributing to cancer research through lipid-nanocarrier drug delivery for endocrine tumors.

Research Interests

Dr. Prakriti Sharma 🔬 is actively engaged in cutting-edge research on inflammation and cancer biology. Her work explores the role of the NFAT signaling pathway in lung inflammation 🫁, aiming to uncover mechanisms behind immune responses. She investigates the anti-inflammatory and apoptotic effects of aptamers, nanoparticles, and bioactive molecules in cancer therapy 🧪🎗️. Additionally, she studies key signaling pathways to understand the complex interactions between immune cells and cancer cells 🧬🔍. Through her research, Dr. Sharma strives to develop innovative therapeutic strategies for inflammatory diseases and cancer treatment, contributing to advancements in biomedical science.

Trainings

Dr. Prakriti Sharma 🎓 has actively participated in various national and international training programs and webinars to enhance her expertise in biomedical research. She completed a Seven-Day National Training on Lab Animals in Biomedical Research 🐭🔬 at MAFSU, Parbhani (2021) and attended a workshop on Bio-methodology & Ethical Use of Laboratory Animals at CSIR-IMTECH, Chandigarh (2022) 📚. She also engaged in international webinars on Drug Discovery – New Lead from Old Drugs 💊 (2020), Alternative Therapies to Mitigate Microbial Resistance 🦠 (2021), and Diagnosis of Bacterial Diseases of Livestock 🐄 (2021), contributing to her growing knowledge in biotechnology and healthcare.

Presentations

Dr. Prakriti Sharma 🎓 has actively contributed to scientific conferences through poster presentations and published abstracts. At VIBCON 2022, she presented her research on Upregulation of IL-4 and IL-13 Following Exposure to Deltamethrin 🧬. She also showcased her study on Transcriptomic Analysis of the Lung After Deltamethrin Exposure at the International e-Symposium on Emerging Focus on Immunology 🫁🔬. In IMMUNOCON 2023, she presented findings on Oleuropein’s Role in Modulating Inflammation and Inducing Cancer Cell Apoptosis 🎗️. Through these contributions, Dr. Sharma continues to advance research in immunology, toxicology, and cancer biology.

Research Focus

Dr. Prakriti Sharma’s research focuses on toxicology, nanomedicine, and molecular biology 🧪🔬. Her work explores the effects of environmental toxins on cellular pathways, including NFAT signaling and lung damage 🫁⚠️. She also investigates nanoparticle-based drug delivery for conditions like rheumatoid arthritis 🏥💊 and malaria treatment 🦟🛡️. Additionally, she studies biogenic nanoparticles for antimicrobial applications and their potential in theranostics—combining diagnostics with targeted therapy 🧬🎯. Dr. Sharma’s interdisciplinary research spans pharmacology, biotechnology, and nanoscience, aiming for innovative therapeutic solutions to combat diseases and environmental hazards 🌍💡.

Publication Top Notes

Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation

A Study on Comparative Antioxidant Properties of Mimosa pudica, Vachellia nilotica, Leucas aspera, Phyllanthus niruri, emidesmus indicus and Adhatoda vasica

Disinfectant-like activity of lipopeptide biosurfactant produced by Bacillus tequilensis strain SDS21

Taro Shibuki | Clinical Trials | Best Researcher Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Liangliang Dai | Drug Delivery Systems | Best Researcher Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Liangliang Dai | Drug Delivery Systems | Best Researcher Award

Prof Liangliang Dai, Northwestern Polytechnical University, China

Prof. Liangliang Dai Associate Professor & Assistant Dean, Institute of Medical Research, Northwestern Polytechnical University. With a PhD and MD in Biomedical Engineering and Biology from Chongqing University under Prof. Kaiyong Cai, Prof. Dai’s research focuses on nanomaterials, drug delivery systems, nanosystems, tumor immunotherapy, and antimetabolic therapy. He has led multiple national and provincial research projects and published in top journals like Nature Communications and Advanced Functional Materials. His innovative work bridges nanotechnology and cancer therapy, advancing biomedical science. 🔬🌿

Publication Profile

orcid

Education Background

Prof. Liangliang Dai holds a Ph.D. in Biomedical Engineering 🎓 from the Ministry of Education College of Bioengineering at Chongqing University, where he conducted advanced research under the mentorship of Prof. Kaiyong Cai. His academic journey also includes an MD in Biology 🧬 from the same institution, further solidifying his expertise in bioengineering and biomedical sciences. Guided by Prof. Cai, his studies focused on cutting-edge innovations in the field. With a strong foundation in interdisciplinary research, Prof. Dai continues to contribute to scientific advancements in biomedical engineering and biology, shaping the future of healthcare and biotechnology 🔬.

Hosted Research Project

Prof. Liangliang Dai has led several prestigious research projects 🔬, contributing significantly to biomedical engineering. He has been awarded funding from the National Natural Science Foundation of China 🏅 for multiple projects (52373157, 52003223) and has received the National Science Foundation for Distinguished Young Scholars of Shaanxi Province (S2025-JC-JQ-0228). Additionally, he has played a key role in the Key R&D Programs of Shaanxi Province (2024SF2-GJHX-26, 2022SF-012) and secured support from the Natural Science Foundation of Shaanxi Province (2019JQ-347) and the Young Talent Fund of University Association for Science and Technology (20200302) 🌍.

Research Contributions

Prof. Liangliang Dai has secured multiple prestigious research grants 🏅, including funding from the National Natural Science Foundation of China and the Key R&D Program of Shaanxi Province. His research focuses on advanced drug delivery systems 💊, tumor immunotherapy 🧬, and biomedical nanotechnology 🔬, making significant contributions to the medical research community. These competitive grants reflect his expertise and the high regard for his work in the scientific field. Through pioneering innovations, Prof. Dai continues to push the boundaries of biomedical engineering, striving for breakthroughs that enhance healthcare and therapeutic solutions globally 🌍.

Global Recognition

Prof. Liangliang Dai is a globally recognized researcher 🌍, collaborating with renowned scientists to develop innovative therapeutic strategies 🔬. His groundbreaking work in cancer therapy 🧬 and nanomaterial-based drug delivery 💊 is paving the way for more effective medical treatments. Beyond securing prestigious grants and publishing impactful research, his contributions hold practical significance in biomedical applications, transforming healthcare solutions. With a commitment to advancing science, Prof. Dai’s influence continues to grow, driving innovation and shaping the future of medicine through cutting-edge technologies and interdisciplinary collaborations 🤝.

Innovative Research

Prof. Liangliang Dai’s research is highly interdisciplinary 🔬, blending nanotechnology, immunotherapy, and bioengineering to advance medical science. His groundbreaking work on multifunctional metal-organic frameworks 🏗️, light-activatable antibiosis for infected bone repair 🦴, and tumor microenvironment modulation 🧬 showcases his pioneering role in translational medicine. By enhancing cancer treatment strategies 🎗️ and optimizing drug delivery systems 💊, his studies have a direct impact on healthcare. Through cutting-edge innovations, Prof. Dai is shaping the future of biomedical science, driving transformative solutions that improve patient outcomes and therapeutic effectiveness worldwide 🌍.

Research Focus

Liangliang Dai’s research primarily focuses on nanotechnology and biomedical engineering 🧪🔬, with a particular emphasis on nanosystems for drug delivery, tumor therapy, and environmental applications. His work explores nanoparticles, metal-organic frameworks (MOFs), and photo-responsive materials to develop advanced cancer treatments 🎗️, chemodynamic therapy ⚛️, immune modulation 🛡️, and antimicrobial strategies 🦠. Dai also investigates water purification 💧 and biofilm control to tackle antibiotic resistance. His research bridges materials science 🏗️ and biomedicine to create multifunctional therapeutic nanosystems, advancing precision medicine 🧬 and environmental health 🌍.

Publication Top Notes

Nanosilver-Induced Pseudo Cuproptosis of Potentially Pathogenic Bacteria during the Storage of Ozone-Treated Wastewater

MMP-2/GSH-responsive nanobomb for tumor chemo-immunotherapy with hierarchical delivery and TAMs re-education by regulating hbegf-activated ERK/MAPK signal pathway

An Adjuvant Micelle-Based Multifunctional Nanosystem for Tumor Immunotherapy by Remodeling Three Types of Immunosuppressive Cells.

Multifunctional Fe-based coordination polymer nano-bomb modified with β-lapachone and CaO2 for targeted tumor dual chemodynamic therapy with enhanced ferroptosis and H2O2 self-supply.

A Photo‐Therapeutic Nanocomposite with Bio‐Responsive Oxygen Self‐Supplying Combats Biofilm Infections and Inflammation from Drug‐Resistant Bacteria

Detachable MOF-Based Core/Shell Nanoreactor for Cancer Dual-Starvation Therapy With Reversing Glucose and Glutamine Metabolisms.

Engineered drug delivery nanosystems for tumor microenvironment normalization therapy

Cascade amplification of tumor chemodynamic therapy and starvation with re-educated TAMs via Fe-MOF based functional nanosystem

Editorial: Advances in the development of functional biomaterial nanosystem in tumor therapy and tissue regeneration.

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Published on 19/02/202519/02/2025 by Top Pharmaceutical

Hui Xiao | Drug Discovery and Development | Pharmaceutical Innovation Achievement Award

Dr Hui Xiao,regeneron,United States

Dr. Hui Xiao 🧪🔬 is a distinguished scientist specializing in biochemistry, structural biology, and mass spectrometry. With a strong focus on microtubule dynamics, protein interactions, and drug mechanisms, he has made significant contributions to understanding cellular processes. As a co-first author and lead researcher, his work has been published in esteemed journals like J. Mol. Biol., Biochemistry, and J. Biol. Chem.. His expertise spans hydrogen-deuterium exchange, proteomics, and molecular stabilization studies. Dr. Xiao’s research has advanced drug discovery, particularly in cancer therapeutics and protein biochemistry. 📚🔍 His innovative approaches continue to impact biomedical sciences globally. 🌍✨

Publication Profile

Scopus

Education

Dr. Hui Xiao 🎓 holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst (2005) and a degree in Applied Chemistry from Peking University, China (1992). Currently serving as an Associate Director at Regeneron Pharmaceuticals 🏢, he specializes in protein characterization using mass spectrometry. With over a decade at Regeneron, he has progressed through roles as a Senior Staff Scientist and Staff Scientist. Previously, he held academic positions at Albert Einstein College of Medicine 🧬, advancing from Instructor to Research Associate Professor. His expertise spans analytical chemistry, protein analysis, and therapeutic protein research, making significant contributions to biomedical science. 🔬

Professional Impact

Dr. Hui Xiao 🎓 is a distinguished scientist with over 20 years of experience in academia and the biotechnology industry. Currently, he serves as an Associate Director of Analytical Chemistry at Regeneron Pharmaceuticals 🏢, a leading biotech company. His expertise lies in mass spectrometry applications for protein characterization 🔬, contributing to advancements in therapeutic development. Before joining Regeneron, Dr. Xiao held esteemed faculty positions at Albert Einstein College of Medicine 🧬, progressing from Instructor to Research Associate Professor. His extensive research and leadership have played a crucial role in bridging analytical chemistry with biopharmaceutical innovation, impacting drug discovery and development. 🚀

Scientific Contributions

Dr. Hui Xiao 🎓 is a leading expert in protein-ligand interactions, structural proteomics, and therapeutic protein analysis 🔬. His pioneering work includes the application of hydrogen-deuterium exchange mass spectrometry (HDX-MS) for epitope mapping 🧩 and microtubule stabilization research. With a deep focus on drug characterization and regulatory sciences, his contributions have significantly advanced biopharmaceutical development 💊. His expertise in mass spectrometry-driven protein analysis has helped enhance the understanding of molecular mechanisms, improving therapeutic strategies. Through innovation and research, Dr. Xiao continues to play a vital role in shaping the future of biopharmaceutical science and drug discovery. 🚀

Potential Considerations

Dr. Hui Xiao 🎓 is a renowned expert in analytical and protein chemistry, with groundbreaking work in epitope mapping and protein characterization 🔬. While his contributions significantly impact drug development, the Pharmaceutical Innovation Achievement Award 🏆 may prioritize direct advancements in drug discovery and novel pharmaceutical interventions 💊. His research has important regulatory and therapeutic implications, but highlighting specific drug innovations or regulatory breakthroughs he has led would further strengthen his case. By showcasing his role in pioneering pharmaceutical advancements, Dr. Xiao’s influence in shaping modern biopharmaceutical science can be fully recognized and appreciated. 🚀

Research Focus

Dr. Hui Xiao’s research primarily focuses on analytical chemistry 🧪, particularly in the quantitative analysis of biomolecules 🧬 using advanced mass spectrometry techniques ⚖️. His work involves CRISPR sgRNA modification analysis 🧬🔬 and the development of LC-MS-based assays for biological therapeutics 💊. He specializes in phosphorothioate isomer detection 🔄 and liquid chromatography-multiple reaction monitoring-mass spectrometry (LC-MRM-MS) 📊 for precise biomolecular quantification. His contributions are crucial in drug discovery 🏥, gene editing 🧬, and biopharmaceutical development 💉. His expertise bridges biotechnology 🔬 and analytical methodologies 📈, advancing innovations in therapeutic monitoring and molecular diagnostics 🏥.

Publication Top Notes

Quantitative Analysis of Phosphorothioate Isomers in CRISPR sgRNA at Single-Residue Resolution Using Endonuclease Digestion Coupled with Liquid Chromatography Cyclic Ion Mobility Mass Spectrometry (LC/cIMS)

Generic Enrichment Method for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Assay for Quantitative Measurement of Biological Therapeutics in Serum

Tang Jin-Bao | Pharmacology | Best Researcher Award

Published on 18/02/202518/02/2025 by Top Pharmaceutical

Tang Jin-Bao | Pharmacology | Best Researcher Award

Prof. Dr Tang Jin-Bao,Shandong Second Medical University,China

Prof. Dr. Jin-Bao Tang, a licensed pharmacist in China, is a professor at Shandong Second Medical University. He earned his Ph.D. in Microbial and Biochemical Pharmacy from Shandong University in 2023. An esteemed graduate sponsor in Shandong Province, he specializes in Biotechnological Pharmaceutics and Pharmaceutical Engineering. His research focuses on developing novel immunoassay biosensors for proteins and peptides. With multiple high-impact publications in Food Chemistry and Analytical Bioanalytical Chemistry, he has pioneered advanced immunosensor technologies. His innovative contributions to biosensor development enhance precision in food safety and biomedical analysis. 🔬📚

Publication Profile

Scopus

Education

Prof. Dr. Jin-Bao Tang 🎓 holds a Doctorate in Microbial and Biochemical Pharmacy from Shandong University (2023) and is a licensed pharmacist in China. As a distinguished professor at Shandong Second Medical University, he plays a vital role in educating future pharmaceutical professionals in Biotechnological Pharmaceutics and Pharmaceutics Engineering 🧪. His dedication to academia is evident through his mentorship and contributions to pharmaceutical sciences. Recognized as an excellent graduate sponsor of Shandong Province 🏆, Dr. Tang’s expertise and commitment continue to shape the next generation of researchers and industry leaders in the field of pharmacy. 💊

Scientific Community

Prof. Dr. Jin-Bao Tang 🧑‍🔬 has made a significant impact in the scientific community through his groundbreaking research in biotechnology and pharmacology. His publications appear in prestigious journals such as Food Chemistry, International Journal of Biological Macromolecules, Food Control, and Analytical Bioanalytical Chemistry 📚. His collaborative work has led to advancements in oriented antibody immobilization, photoconjugation strategies, and biosensor technology 🧪, with profound implications for public health, biotechnology, and pharmacological applications. Through his innovative contributions, Prof. Tang continues to shape the future of pharmaceutical sciences, enhancing diagnostic and therapeutic approaches for global healthcare. 🌍💊

Research Contributions

Prof. Dr. Tang Jin-Bao’s research revolves around developing novel immunoassay biosensors for protein and peptide detection 🧪🔬. His pioneering work has significantly advanced biosensing technology, particularly in food safety and biomedical analysis 🍎⚕️. Over the past five years, his high-impact publications have introduced innovative techniques such as electrochemical immunosensors for aflatoxin detection ⚡, bioluminescent immunoassays using antibody-nanoluciferase conjugates ✨, and Fc-specific antibody modifications for enhanced biosensor performance 🧫. Additionally, his photoconjugation strategies have led to stable fluorescent antibody fabrication 🌟. These breakthroughs contribute immensely to food safety, pharmaceutical analysis, and immunodiagnostics, demonstrating the real-world impact of his research. 🚀

Research Focus

Prof. Dr. Jin-Bao Tang’s research primarily focuses on biosensors 🧪, immunoassays 🏥, and antibody engineering 🧬 for food safety and biomedical applications. His work involves developing electrochemical immunosensors ⚡, bioluminescent assays 💡, and advanced antibody modifications 🏗️ to enhance the detection of harmful contaminants like aflatoxin B1 🍄⚠️. He explores oriented antibody immobilization 🎯 to improve sensitivity and specificity in bioanalytical methods. Additionally, his research extends to drug delivery systems 💊, particularly in pulsatile release formulations ⏳, using innovative polymers. His contributions advance food safety 🥗, biomedical diagnostics 🏥, and pharmaceutical technologies 💊 for global health and safety.

Publication Top Notes

A facile and effective electrochemical immunosensor based on controlled and oriented immobilization of natural antibodies for sensitive detection of aflatoxin B₁

Development of a bioluminescent immunoassay based on Fc-specific conjugated antibody–nanoluciferase immunoreagents for determining aflatoxin B₁

Fabrication of cysteine-modified antibodies with Fc-specific conjugation for covalent and oriented immobilization of native antibodies

Preparation of enteric capsules with pulsatile drug delivery potential using pullulan and polyacrylic acid resin III

Muhammad Ayub | Drug Discovery and Development | Best Researcher Award

Published on 14/02/202514/02/2025 by Top Pharmaceutical

Muhammad Ayub | Drug Discovery and Development | Best Researcher Award

Dr Muhammad Ayub,University of Sahiwal,Pakistan

Dr. Muhammad Ayub 🎓🔬 is an accomplished analytical chemist specializing in the extraction, purification, and characterization of bioactive compounds from plant materials. He earned his Ph.D. in Analytical Chemistry from the University of Agriculture Faisalabad, Pakistan (2018). With expertise in advanced chromatographic techniques (HPLC, GC-MS, NMR) and biological assays, he has contributed significantly to sustainable extraction methodologies. As a Principal Investigator at the University of Sahiwal, he led research on cost-effective extraction of volatile bioactives. His international experience includes research at The University of Queensland, Australia. Passionate about innovation, he mentors students in analytical chemistry and bioactive research. 🌿

Education

Dr. Muhammad Ayub 🎓 is a distinguished analytical chemist from Pakistan with an impressive academic background. He earned his Ph.D. in Analytical Chemistry in 2018 from the University of Agriculture Faisalabad 🏛️. Prior to this, he completed his M.Phil. in Analytical Chemistry in 2011 from Government College University Faisalabad 📚. His journey in chemistry began with an M.Sc. in Analytical Chemistry in 2009 from the University of Agriculture Faisalabad, following a B.Sc. in Chemistry, Zoology, and Geography from Government College University Faisalabad in 2007 🔬. His expertise contributes significantly to research and advancements in analytical sciences. 🔍✨

Research Statement

Dr. Muhammad Ayub is an expert in the extraction, isolation, and characterization of bioactive compounds from plant materials 🌿. He utilizes advanced techniques such as hydro distillation, steam distillation, microwave-assisted extraction, superheated steam extraction, and supercritical fluid extraction ⚗️. His research focuses on optimizing essential oil extraction to enhance yield and quality while exploring the role of micronutrients in plant growth 🌱. With expertise in chromatographic methods and characterization tools like GC-MS, LC-MS, and NMR 🔬, he evaluates antibacterial, antifungal, antioxidant, and antitumor activities 🦠. His pioneering work in superheated steam extraction has revolutionized sustainable and efficient methodologies. 🚀

Research Experience

Dr. Muhammad Ayub is a dedicated researcher specializing in the extraction and characterization of bioactive compounds. As a Principal Investigator at the University of Sahiwal (2022–2024) 🏛️, he led an HEC-NRPU project focusing on cost-effective methods for extracting volatile bioactives from oleo-gum resins 🌿. His expertise spans superheated steam extraction, bioactive purification, and antimicrobial assessments 🧪. With postgraduate research experience in Pakistan and Australia 🇦🇺, he has worked extensively on chromatographic techniques, essential oil purification, and antioxidant studies. His mentorship has guided numerous students in advanced extraction techniques, making significant contributions to natural product chemistry 🔬.

Teaching Experience

Dr. Muhammad Ayub is a dedicated lecturer in chemistry at the University of Sahiwal, where he has been serving permanently since March 2020 🏫. He supervises research students and teaches analytical chemistry at both undergraduate and postgraduate levels 🧪. Previously, he worked as an Assistant Professor at the University of Okara (Feb 2019 – Feb 2020) on a one-year contract, instructing analytical and inorganic chemistry 📚. Before that, he was a Guest Assistant Professor at the same university (Oct 2018 – Feb 2019), specializing in analytical chemistry at the undergraduate level. His expertise and passion for teaching continue to inspire students 🎓.

Academic Service

Dr. Muhammad Ayub has held several key academic and administrative positions in Pakistan. He served as the Coordinator for the BS Chemistry Program at the University of Okara from February 2019 to February 2020 🧪. Currently, he is the In-Charge of Chemical Laboratories at the University of Sahiwal, a role he has held since January 2021 🏛️. Additionally, he worked as the Deputy Director of ORIC at the University of Sahiwal from June 2022 to January 2023 📊. Since February 2023, he has been the Focal Person for the Higher Education Commission at the University of Sahiwal 🎓.

Awards

Dr.Muhammad Ayub has earned numerous prestigious accolades throughout his career. In 2017, he was awarded the International Research Support Initiative Program (IRSIP) by the Higher Education Commission (HEC) of Pakistan to conduct research at The University of Queensland, Australia 🇦🇺. In 2019, he secured the Interim Placement Program for Fresh PhDs (IPFP-HEC) 🏅. The same year, he achieved first position 🥇 in a paper presentation at the 1st National Conference on Multidisciplinary Research (NCMR-2019), University of Okara. Additionally, he won a highly competitive research grant of 2.71 million PKR 💰 under the National Research Program for Universities (NRPU-HEC).

Training Workshop

Dr. Muhammad Ayub has actively participated in various workshops and training programs to enhance his research and scientific writing skills. On February 26, 2018, he attended a workshop on “Writing Scientific Research” 📄 at the Department of Chemistry, University of Agriculture, Faisalabad. He further honed his expertise by joining a “Bioassays for Exploration of Bioactivities” 🧪 training session on March 20, 2018, at the Department of Biochemistry. Additionally, on December 16, 2019, he attended a prestigious training session at Tel Aviv University 🎓 on “How to Write a Great Research Paper and Get it Accepted”, presented by Elsevier experts.

Research Focus

Dr. Muhammad Ayub’s research primarily focuses on essential oil extraction, natural product chemistry, and material science 🧪🌿. His studies involve optimizing short-path molecular distillation, superheated steam distillation, and other advanced extraction techniques for obtaining bioactive compounds from plants 🌱. He investigates the antioxidant, antimicrobial, and pharmacological properties of essential oils, comparing conventional and innovative extraction methods 🔬. Additionally, his work extends to polymer chemistry, particularly the use of biopolymers like carboxymethyl cellulose in polyurethane synthesis for thermal applications 🔥. His interdisciplinary approach bridges natural product chemistry, pharmacology, and material science to develop functional bioactive compounds.

Publication Top Notes

Short path molecular distillation of the essential oil from Pinus roxburghii oleoresin affords volatile fractions with powerful antioxidant and antimicrobial activities comparable with common synthetic agents and antimicrobials

Use of carboxymethyl cellulose in polyurethane synthesis for thermal applications

Comparative Pharmacological Potential of Cumin (Cuminum cyminum) Seed Essential Oils: Conventional vs. Superheated Steam Distillation

Comparative Study of Essential Oils Extracted From Foeniculum vulgare Miller Seeds Using Hydrodistillation, Steam Distillation, and Superheated Steam Distillation

Optimizing the extraction of essential oil yield from Pistacia lentiscus oleo-gum resin by superheated steam extraction using response surface methodology

Chuan Fan | Nanomedicine | Best Researcher Award

Published on 14/02/202514/02/2025 by Top Pharmaceutical

Chuan Fan | Nanomedicine | Best Researcher Award

Dr Chuan Fan,Linyi University,China

Dr. Chuan Fan 🎓🔬 is a lecturer at Linyi University’s School of Chemistry and Chemical Engineering, specializing in multifunctional hydrogel dressing systems and acoustic-driven biomarker analysis. He earned his degree from the University of Science and Technology Beijing under Prof. Xueji Zhang. With 30+ SCI- and Scopus-indexed publications and a ResearchGate citation index of 984, his research contributes to pharmacology and drug delivery. However, he is in the early stages of securing patents, grants, and industry collaborations. His work holds promise for advanced therapeutic applications, making him a strong contender for early-career research awards. 🏆📚

Publication Profile

Scopus

Academic and Professional Background

Dr. Chuan Fan 🎓 pursued his studies at the University of Science and Technology Beijing under the esteemed mentorship of Professor Xueji Zhang. Since August 2023, he has been serving as a lecturer at Linyi University’s School of Chemistry and Chemical Engineering 🏫. His research primarily focuses on multifunctional hydrogel dressing systems and acoustic-driven enrichment analysis of trace biomarkers 🧪. Through his dedication and innovation, Dr. Fan has made significant progress in his field, contributing to multiple high-quality publications in indexed journals 📚. His work continues to advance scientific knowledge and practical applications in chemical and biomedical research. 🚀

Research and Innovations

Dr. Chuan Fan has made notable contributions to his field, authoring over 30 SCI- and Scopus-indexed articles 📄, reflecting his dedication to research. His citation index on ResearchGate stands at 984 🔍, indicating a moderate academic impact. However, his research engagement appears to be in its early stages, with no completed projects and only two ongoing ones 🧪. Despite his publication record, he has yet to secure patents, editorial appointments, industry collaborations, consultancy projects, or book publications 📚. While his work is promising, further achievements in these areas could enhance his influence in the scientific community. 🌟

Contributions and Impact

Dr. Chuan Fan is dedicated to advancing pharmacology and drug delivery systems, with a focus on enhancing targeted therapies and improving patient outcomes 💊🔬. His research explores innovative methods to optimize drug efficacy and minimize side effects, contributing to the evolving landscape of precision medicine. While he asserts that his work has gained significant recognition, concrete evidence such as prestigious awards, keynote invitations, or high-impact citations remains unspecified 🏆📖. Despite this, his contributions reflect a commitment to revolutionizing drug delivery, potentially shaping future advancements in personalized treatment strategies for various medical conditions 🚀🧬.

Professional Engagements

Dr. Chuan Fan currently does not hold any professional memberships, editorial roles, or collaborative positions, which are key indicators of a researcher’s influence in the academic community 📚. Actively participating in international conferences 🌍, joining professional societies 🏛️, and engaging in research networks 🔬 would significantly enhance his professional standing. Such involvement fosters knowledge exchange, strengthens collaborations, and increases visibility within the scientific community. By contributing to peer-reviewed journals ✍️, networking with experts 🤝, and taking on leadership roles, Dr. Fan can expand his impact and establish himself as a recognized authority in his field of expertise.

Research Focus

Dr. Chuan Fan’s research focuses on biomedical materials 🧪, nanotechnology 🧫, and wound healing 🩹, particularly in developing visible light-activated Ti-MOF (titanium-metal-organic frameworks) hydrogel composites for chronic diabetic wound healing 🦶. His work integrates photocatalysis 🌞, drug delivery 💊, and biocompatible hydrogels to enhance tissue regeneration and antimicrobial effects. By loading metformin into these advanced biomaterials, Dr. Fan aims to promote faster and more effective healing of diabetic wounds, addressing a critical medical challenge. His research sits at the intersection of materials science 🏗️, biomedical engineering ⚙️, and regenerative medicine 🧬.

Publication Top Notes

Visible light-activated Ti-MOF loaded metformin-hydrogel composite dressing for accelerated chronic diabetic wound healing

Bo Meng | Pharmaceutical Biotechnology | Top Pharmaceutical Scientist Award

Published on 13/02/202513/02/2025 by Top Pharmaceutical

Bo Meng | Pharmaceutical Biotechnology | Top Pharmaceutical Scientist Award

Dr Bo Meng, WuXi Biologics, China

🔬 Dr. Bo Meng is an Associate Director at WuXi Biologics, Shanghai 🇨🇳 (2017–present), leading 30+ CMC projects for biologics like antibodies, enzymes, and vaccines. 💉 He manages a team of 20+ scientists, driving innovations from pre-IND to BLA filings. Previously, he was a Research Scientist at Omicron Biochemicals, USA 🇺🇸, focusing on glycan synthesis. 🧪 Dr. Meng earned his Ph.D. in Organic Chemistry from the University of Tennessee 🎓 and a B.Sc. in Applied Chemistry from Beijing Institute of Technology. 📖 His research is published in top journals, and he holds a Lean Six Sigma Green Belt. 🏆

Publication Profile

Orcid

Education

Dr. Bo Meng 🎓 earned a Ph.D. in Organic Chemistry 🧪 from the University of Tennessee, Knoxville 🇺🇸, completing his studies in August 2015. His academic journey began at Beijing Institute of Technology 🇨🇳, where he obtained a Bachelor’s degree in Applied Chemistry ⚗️ in June 2010. With a strong foundation in chemical sciences and research, Dr. Meng has developed expertise in organic synthesis and chemical applications. His educational background reflects a dedication to advancing scientific knowledge and contributing to innovative research in the field of chemistry 🔍🔬.

Working Experience

Dr. Bo Meng is the Associate Director at WuXi Biologics in Shanghai, China (2017–present) 🇨🇳🔬. With expertise in biologics development, he leads 30+ CMC projects, including antibodies, fusion proteins, ADCs, enzymes, vaccines, and mRNA 💉🧬. As Project Head, he oversees cell line development, process optimization, and regulatory filings from pre-IND to BLA 📑⚙️. He also manages a 20-person analytical team, ensuring robust assay development, product stability, and regulatory compliance. Previously, he worked at Omicron Biochemicals Inc. in the USA (2015–2017) 🇺🇸⚗️, contributing significantly to innovative biopharmaceutical advancements.

Research Scientist

Dr. Bo Meng specializes in the chemical and enzymatic synthesis, purification, and analysis of oligosaccharides 🧪, with a focus on high-mannose N-glycans, mannose phosphates, and 13C-labeled sugars 🧬. These complex carbohydrates play a crucial role as therapeutic targets in pathology and immunological studies 🩺🛡️. Through innovative research and advanced analytical techniques, Dr. Meng contributes to the development of new treatments and diagnostic tools for various diseases. Their work bridges the gap between biochemical research and medical applications, enhancing our understanding of immune responses and disease mechanisms for better healthcare solutions 🌱💡.

Research Focus

Dr. Bo Meng’s research spans biopharmaceuticals, carbohydrate chemistry, and materials science. 🧪🔬 His recent work investigates excipient impacts on polysorbate 80 degradation in biopharmaceutical formulations. 💉🧫 He has explored regioselective glycosylation to synthesize high-mannose oligosaccharides with mannose-6-phosphate residues. 🍬⚛️ Additionally, Dr. Meng has contributed to developing hyper-crosslinked cyclodextrin polymers for efficient CO₂ capture and catalytic applications. 🌿🛠️ His innovative work in carbohydrate-based materials showcases potential for green chemistry, biotechnology, and drug formulation. 🌏💊 Through interdisciplinary approaches, he advances solutions for environmental challenges and pharmaceutical stability. 📈🔍